{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:37:24Z","timestamp":1790534244418,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000404","name":"foundation for liver research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"australian research council","doi-asserted-by":"crossref","award":["DP190102555"],"award-info":[{"award-number":["DP190102555"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"name":"singapore ministry of health via the duke-nus signature research programmes","award":["MOH-000032\/MOH-CIRG18may-0004"],"award-info":[{"award-number":["MOH-000032\/MOH-CIRG18may-0004"]}]},{"DOI":"10.13039\/100001082","name":"Camille and Henry Dreyfus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001082","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health","award":["R35 GM13779501"],"award-info":[{"award-number":["R35 GM13779501"]}]},{"name":"CRUK-OHSU Project Award","award":["(C52489\/A29681)"],"award-info":[{"award-number":["(C52489\/A29681)"]}]},{"name":"CRUK Accelerator award to the HUNTER consortium","award":["(C18873\/A26813)."],"award-info":[{"award-number":["(C18873\/A26813)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is increasing worldwide, but the steps in precancerous hepatocytes which lead to HCC driver mutations are not well understood. Here we provide evidence that metabolically driven histone hyperacetylation in steatotic hepatocytes can increase DNA damage to initiate carcinogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Global epigenetic state was assessed in liver samples from high-fat diet or high-fructose diet rodent models, as well as in cultured immortalized human hepatocytes (IHH cells). The mechanisms linking steatosis, histone acetylation and DNA damage were investigated by computational metabolic modelling as well as through manipulation of IHH cells with metabolic and epigenetic inhibitors. Chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) and transcriptome (RNA-seq) analyses were performed on IHH cells. Mutation locations and patterns were compared between the IHH cell model and genome sequence data from preneoplastic fatty liver samples from patients with alcohol-related liver disease and NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Genome-wide histone acetylation was increased in steatotic livers of rodents fed high-fructose or high-fat diet. In vitro, steatosis relaxed chromatin and increased DNA damage marker \u03b3H2AX, which was reversed by inhibiting acetyl-CoA production. Steatosis-associated acetylation and \u03b3H2AX were enriched at gene clusters in telomere-proximal regions which contained HCC tumour suppressors in hepatocytes and human fatty livers. Regions of metabolically driven epigenetic change also had increased levels of DNA mutation in non-cancerous tissue from NAFLD and alcohol-related liver disease patients. Finally, genome-scale network modelling indicated that redox balance could be a key contributor to this mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Abnormal histone hyperacetylation facilitates DNA damage in steatotic hepatocytes and is a potential initiating event in hepatocellular carcinogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-022-01071-5","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T06:06:44Z","timestamp":1655964404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Gabriella","family":"Assante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Tourna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kowsar A.","family":"Isse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Soffientini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Rozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William O.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Chokshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Youngson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"1071_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604. https:\/\/doi.org\/10.1038\/s41575-019-0186-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1071_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.28524","volume":"64","author":"M Rinella","year":"2016","unstructured":"Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64:19\u201322. https:\/\/doi.org\/10.1002\/hep.28524.","journal-title":"Hepatology"},{"key":"1071_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338. https:\/\/doi.org\/10.1038\/s41575-020-00381-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1071_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71:808\u201319. https:\/\/doi.org\/10.1002\/hep.31014.","journal-title":"Hepatology"},{"key":"1071_CR5","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828-1837 e1822. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.024.","journal-title":"Gastroenterology"},{"key":"1071_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze K, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505\u201311. https:\/\/doi.org\/10.1038\/ng.3252.","journal-title":"Nat Genet"},{"key":"1071_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41575-019-0165-3","volume":"16","author":"JC Nault","year":"2019","unstructured":"Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019;16:544\u201358. https:\/\/doi.org\/10.1038\/s41575-019-0165-3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1071_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.052","author":"M Ningarhari","year":"2020","unstructured":"Ningarhari M, et al. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.052.","journal-title":"J Hepatol"},{"key":"1071_CR9","doi-asserted-by":"publisher","first-page":"637027","DOI":"10.1155\/2014\/637027","volume":"2014","author":"AM Gusdon","year":"2014","unstructured":"Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev. 2014;2014:637027. https:\/\/doi.org\/10.1155\/2014\/637027.","journal-title":"Oxid Med Cell Longev"},{"key":"1071_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41580-018-0029-7","volume":"19","author":"X Li","year":"2018","unstructured":"Li X, Egervari G, Wang Y, Berger SL, Lu Z. Regulation of chromatin and gene expression by metabolic enzymes and metabolites. Nat Rev Mol Cell Biol. 2018;19:563\u201378. https:\/\/doi.org\/10.1038\/s41580-018-0029-7.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1071_CR11","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1126\/science.1164097","volume":"324","author":"KE Wellen","year":"2009","unstructured":"Wellen KE, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324:1076\u201380. https:\/\/doi.org\/10.1126\/science.1164097.","journal-title":"Science"},{"key":"1071_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40170-015-0135-3","volume":"3","author":"AA Cluntun","year":"2015","unstructured":"Cluntun AA, et al. The rate of glycolysis quantitatively mediates specific histone acetylation sites. Cancer Metab. 2015;3:10. https:\/\/doi.org\/10.1186\/s40170-015-0135-3.","journal-title":"Cancer Metab"},{"key":"1071_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.celrep.2016.10.012","volume":"17","author":"E McDonnell","year":"2016","unstructured":"McDonnell E, et al. Lipids reprogram metabolism to become a major carbon source for histone acetylation. Cell Rep. 2016;17:1463\u201372. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.012.","journal-title":"Cell Rep"},{"key":"1071_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cmet.2016.12.017","volume":"25","author":"RJ Perry","year":"2017","unstructured":"Perry RJ, Peng L, Cline GW, Petersen KF, Shulman GI. A Non-invasive method to assess hepatic acetyl-CoA in vivo. Cell Metab. 2017;25:749\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2016.12.017.","journal-title":"Cell Metab"},{"key":"1071_CR15","doi-asserted-by":"publisher","unstructured":"Fletcher, J. A. et al. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCI Insight. 2019;5. https:\/\/doi.org\/10.1172\/jci.insight.127737.","DOI":"10.1172\/jci.insight.127737"},{"key":"1071_CR16","doi-asserted-by":"publisher","unstructured":"Baylin, S. B. & Jones, P. A. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 2016;8. https:\/\/doi.org\/10.1101\/cshperspect.a019505.","DOI":"10.1101\/cshperspect.a019505"},{"key":"1071_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature14221","volume":"518","author":"P Polak","year":"2015","unstructured":"Polak P, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature. 2015;518:360\u20134. https:\/\/doi.org\/10.1038\/nature14221.","journal-title":"Nature"},{"key":"1071_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/bfgp\/elx018","volume":"17","author":"LT Kagohara","year":"2018","unstructured":"Kagohara LT, et al. Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief Funct Genomics. 2018;17:49\u201363. https:\/\/doi.org\/10.1093\/bfgp\/elx018.","journal-title":"Brief Funct Genomics"},{"key":"1071_CR19","doi-asserted-by":"publisher","first-page":"e11725","DOI":"10.7759\/cureus.11725","volume":"12","author":"C Hillyar","year":"2020","unstructured":"Hillyar C, Rallis KS, Varghese J. Advances in epigenetic cancer therapeutics. Cureus. 2020;12:e11725. https:\/\/doi.org\/10.7759\/cureus.11725.","journal-title":"Cureus"},{"key":"1071_CR20","doi-asserted-by":"publisher","unstructured":"Garmpis, N. et al. Histone deacetylase inhibitors in the treatment of hepatocellular carcinoma: current evidence and future opportunities. J Pers Med 2021;11. https:\/\/doi.org\/10.3390\/jpm11030223.","DOI":"10.3390\/jpm11030223"},{"key":"1071_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.4103\/1008-682X.163190","volume":"18","author":"NA Youngson","year":"2016","unstructured":"Youngson NA, et al. Obesity-induced sperm DNA methylation changes at satellite repeats are reprogrammed in rat offspring. Asian J Androl. 2016;18:930\u20136. https:\/\/doi.org\/10.4103\/1008-682X.163190.","journal-title":"Asian J Androl"},{"key":"1071_CR22","doi-asserted-by":"publisher","first-page":"18474","DOI":"10.1038\/srep18474","volume":"5","author":"MK Montgomery","year":"2015","unstructured":"Montgomery MK, et al. Disparate metabolic response to fructose feeding between different mouse strains. Sci Rep. 2015;5:18474. https:\/\/doi.org\/10.1038\/srep18474.","journal-title":"Sci Rep"},{"key":"1071_CR23","unstructured":"Assante, G. & Youngson, N. A. Control and oleic acid treated immortalised human hepatocyte (IHH) cell line H4K16ac, GammaH2AX ChIPseq PRJNA741105. NIH National Library of Medicine BioProject (2022)."},{"key":"1071_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nmeth.1226","volume":"5","author":"A Mortazavi","year":"2008","unstructured":"Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621\u20138. https:\/\/doi.org\/10.1038\/nmeth.1226.","journal-title":"Nat Methods"},{"key":"1071_CR25","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106. https:\/\/doi.org\/10.1186\/gb-2010-11-10-r106.","journal-title":"Genome Biol"},{"key":"1071_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","volume":"598","author":"SWK Ng","year":"2021","unstructured":"Ng SWK, et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature. 2021;598:473\u20138. https:\/\/doi.org\/10.1038\/s41586-021-03974-6.","journal-title":"Nature"},{"key":"1071_CR27","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.21105\/joss.03167","volume":"6","author":"I Patil","year":"2021","unstructured":"Patil I. Visualizations with statistical details: The \u201cggstatsplot\u201d approach. J Open Source Softw. 2021;6:3167.","journal-title":"J Open Source Softw"},{"key":"1071_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3.","journal-title":"Nature"},{"key":"1071_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cell.2015.05.019","volume":"161","author":"EJ O'Brien","year":"2015","unstructured":"O\u2019Brien EJ, Monk JM, Palsson BO. Using genome-scale models to predict biological capabilities. Cell. 2015;161:971\u201387. https:\/\/doi.org\/10.1016\/j.cell.2015.05.019.","journal-title":"Cell"},{"key":"1071_CR30","doi-asserted-by":"publisher","first-page":"e2000083","DOI":"10.1002\/bies.202000083","volume":"42","author":"SE Campit","year":"2020","unstructured":"Campit SE, Meliki A, Youngson NA, Chandrasekaran S. Nutrient sensing by histone marks: reading the metabolic histone code using tracing, omics, and modeling. BioEssays. 2020;42:e2000083. https:\/\/doi.org\/10.1002\/bies.202000083.","journal-title":"BioEssays"},{"key":"1071_CR31","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1073\/pnas.0610772104","volume":"104","author":"NC Duarte","year":"2007","unstructured":"Duarte NC, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. P Natl Acad Sci USA. 2007;104:1777\u201382. https:\/\/doi.org\/10.1073\/pnas.0610772104.","journal-title":"P Natl Acad Sci USA"},{"key":"1071_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13059-019-1661-z","volume":"20","author":"F Shen","year":"2019","unstructured":"Shen F, Boccuto L, Pauly R, Srikanth S, Chandrasekaran S. Genome-scale network model of metabolism and histone acetylation reveals metabolic dependencies of histone deacetylase inhibitors. Genome Biol. 2019;20:49. https:\/\/doi.org\/10.1186\/s13059-019-1661-z.","journal-title":"Genome Biol"},{"key":"1071_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/978-1-4939-9224-9_14","volume":"1975","author":"F Shen","year":"2019","unstructured":"Shen F, Cheek C, Chandrasekaran S. Dynamic network modeling of stem cell metabolism. Methods Mol Biol. 2019;1975:305\u201320. https:\/\/doi.org\/10.1007\/978-1-4939-9224-9_14.","journal-title":"Methods Mol Biol"},{"key":"1071_CR34","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1242\/jcs.058271","volume":"123","author":"G Gerlitz","year":"2010","unstructured":"Gerlitz G, Bustin M. Efficient cell migration requires global chromatin condensation. J Cell Sci. 2010;123:2207\u201317. https:\/\/doi.org\/10.1242\/jcs.058271.","journal-title":"J Cell Sci"},{"key":"1071_CR35","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00204-019-02511-9","volume":"93","author":"B Kopp","year":"2019","unstructured":"Kopp B, Khoury L, Audebert M. Validation of the gammaH2AX biomarker for genotoxicity assessment: a review. Arch Toxicol. 2019;93:2103\u201314. https:\/\/doi.org\/10.1007\/s00204-019-02511-9.","journal-title":"Arch Toxicol"},{"key":"1071_CR36","doi-asserted-by":"publisher","first-page":"ARTN 1979","DOI":"10.3390\/ijms18091979","volume":"18","author":"A Georgoulis","year":"2017","unstructured":"Georgoulis A, Vorgias CE, Chrousos GP, Rogakou EP. Genome instability and gamma H2AX. Int J Mol Sci. 2017;18:ARTN 1979. https:\/\/doi.org\/10.3390\/ijms18091979.","journal-title":"Int J Mol Sci"},{"key":"1071_CR37","doi-asserted-by":"publisher","first-page":"e0166956","DOI":"10.1371\/journal.pone.0166956","volume":"11","author":"EE Bankoglu","year":"2016","unstructured":"Bankoglu EE, et al. Role of PTEN in Oxidative Stress and DNA Damage in the liver of whole-body Pten haplodeficient mice. PLoS ONE. 2016;11:e0166956. https:\/\/doi.org\/10.1371\/journal.pone.0166956.","journal-title":"PLoS ONE"},{"key":"1071_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2012.10.031","volume":"58","author":"A Aravinthan","year":"2013","unstructured":"Aravinthan A, et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol. 2013;58:549\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2012.10.031.","journal-title":"J Hepatol"},{"key":"1071_CR39","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1670-9","volume":"574","author":"SF Brunner","year":"2019","unstructured":"Brunner SF, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature. 2019;574:538\u201342. https:\/\/doi.org\/10.1038\/s41586-019-1670-9.","journal-title":"Nature"},{"key":"1071_CR40","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.1074\/jbc.M117.781401","volume":"292","author":"D Wu","year":"2017","unstructured":"Wu D, et al. O-Linked N-acetylglucosamine transferase 1 regulates global histone H4 acetylation via stabilization of the nonspecific lethal protein NSL3. J Biol Chem. 2017;292:10014\u201325. https:\/\/doi.org\/10.1074\/jbc.M117.781401.","journal-title":"J Biol Chem"},{"key":"1071_CR41","doi-asserted-by":"publisher","first-page":"41890","DOI":"10.18632\/oncotarget.17462","volume":"8","author":"D Gentilini","year":"2017","unstructured":"Gentilini D, et al. Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach. Oncotarget. 2017;8:41890\u2013902. https:\/\/doi.org\/10.18632\/oncotarget.17462.","journal-title":"Oncotarget"},{"key":"1071_CR42","doi-asserted-by":"publisher","first-page":"ARTN 194691","DOI":"10.1016\/j.bbagrm.2021.194691","volume":"1864","author":"N Morral","year":"2021","unstructured":"Morral N, et al. Aberrant gene expression induced by a high fat diet is linked to H3K9 acetylation in the promoter-proximal region. Bba-Gene Regul Mech. 2021;1864:ARTN 194691. https:\/\/doi.org\/10.1016\/j.bbagrm.2021.194691.","journal-title":"Bba-Gene Regul Mech"},{"key":"1071_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5114\/ceh.2020.102153","volume":"6","author":"KC Thandra","year":"2020","unstructured":"Thandra KC, et al. Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clin Exp Hepatol. 2020;6:289\u201394. https:\/\/doi.org\/10.5114\/ceh.2020.102153.","journal-title":"Clin Exp Hepatol"},{"key":"1071_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262.","journal-title":"CA Cancer J Clin"},{"key":"1071_CR45","doi-asserted-by":"publisher","first-page":"e106048","DOI":"10.15252\/embj.2020106048","volume":"40","author":"A Lagnado","year":"2021","unstructured":"Lagnado A, et al. Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. EMBO J. 2021;40:e106048. https:\/\/doi.org\/10.15252\/embj.2020106048.","journal-title":"EMBO J"},{"key":"1071_CR46","doi-asserted-by":"publisher","first-page":"589929","DOI":"10.3389\/fimmu.2020.589929","volume":"11","author":"M Dratwa","year":"2020","unstructured":"Dratwa M, Wysoczanska B, Lacina P, Kubik T, Bogunia-Kubik K. TERT-regulation and roles in cancer formation. Front Immunol. 2020;11:589929. https:\/\/doi.org\/10.3389\/fimmu.2020.589929.","journal-title":"Front Immunol"},{"key":"1071_CR47","doi-asserted-by":"publisher","unstructured":"Muresanu, C. et al. Updated understanding of cancer as a metabolic and telomere-driven disease, and proposal for complex personalized treatment, a hypothesis. Int J Mol Sci 2020;21. https:\/\/doi.org\/10.3390\/ijms21186521.","DOI":"10.3390\/ijms21186521"},{"key":"1071_CR48","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1172\/JCI90253","volume":"127","author":"D Lee","year":"2017","unstructured":"Lee D, et al. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017;127:1856\u201372. https:\/\/doi.org\/10.1172\/JCI90253.","journal-title":"J Clin Invest"},{"key":"1071_CR49","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.cmet.2019.05.013","volume":"29","author":"CC Hughey","year":"2019","unstructured":"Hughey CC, Crawford PA. Pyruvate carboxylase wields a double-edged metabolic sword. Cell Metab. 2019;29:1236\u20138. https:\/\/doi.org\/10.1016\/j.cmet.2019.05.013.","journal-title":"Cell Metab"},{"key":"1071_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/excr.1997.3893","volume":"239","author":"S Petersen","year":"1998","unstructured":"Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res. 1998;239:152\u201360. https:\/\/doi.org\/10.1006\/excr.1997.3893.","journal-title":"Exp Cell Res"},{"issue":"Suppl 1","key":"1071_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4\u201313. https:\/\/doi.org\/10.1002\/hep.31288.","journal-title":"Hepatology"},{"key":"1071_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tgh-20-125","volume":"6","author":"P Prasun","year":"2021","unstructured":"Prasun P, Ginevic I, Oishi K. Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. Transl Gastroenterol Hepatol. 2021;6:4. https:\/\/doi.org\/10.21037\/tgh-20-125.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1071_CR53","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","volume":"36","author":"S Francque","year":"2019","unstructured":"Francque S, Vonghia L. Pharmacological treatment for non-alcoholic fatty liver disease. Adv Ther. 2019;36:1052\u201374. https:\/\/doi.org\/10.1007\/s12325-019-00898-6.","journal-title":"Adv Ther"},{"key":"1071_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.aaz8455","volume":"368","author":"O Gilan","year":"2020","unstructured":"Gilan O, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368:387\u201394. https:\/\/doi.org\/10.1126\/science.aaz8455.","journal-title":"Science"},{"key":"1071_CR55","doi-asserted-by":"publisher","first-page":"17257","DOI":"10.1038\/s41598-018-35653-4","volume":"8","author":"SA Middleton","year":"2018","unstructured":"Middleton SA, et al. BET inhibition improves NASH and liver fibrosis. Sci Rep. 2018;8:17257. https:\/\/doi.org\/10.1038\/s41598-018-35653-4.","journal-title":"Sci Rep"},{"key":"1071_CR56","doi-asserted-by":"publisher","first-page":"7440","DOI":"10.1038\/s41598-020-64293-w","volume":"10","author":"M Majeed","year":"2020","unstructured":"Majeed M, Majeed S, Nagabhushanam K, Lawrence L, Mundkur L. Novel combinatorial regimen of garcinol and curcuminoids for non-alcoholic steatohepatitis (NASH) in Mice. Sci Rep. 2020;10:7440. https:\/\/doi.org\/10.1038\/s41598-020-64293-w.","journal-title":"Sci Rep"},{"key":"1071_CR57","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba R, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155:1463-1473 e1466. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.027.","journal-title":"Gastroenterology"},{"key":"1071_CR58","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","volume":"73","author":"J Bates","year":"2020","unstructured":"Bates J, et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol. 2020;73:896\u2013905. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.037.","journal-title":"J Hepatol"},{"key":"1071_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","volume":"29","author":"N Alkhouri","year":"2020","unstructured":"Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29:135\u201341. https:\/\/doi.org\/10.1080\/13543784.2020.1668374.","journal-title":"Expert Opin Investig Drugs"},{"key":"1071_CR60","doi-asserted-by":"publisher","first-page":"729","DOI":"10.21037\/atm-20-4354","volume":"9","author":"F Tacke","year":"2021","unstructured":"Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med. 2021;9:729. https:\/\/doi.org\/10.21037\/atm-20-4354.","journal-title":"Ann Transl Med"}],"updated-by":[{"DOI":"10.1186\/s13073-023-01190-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000}}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01071-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01071-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01071-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T06:03:36Z","timestamp":1684389816000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01071-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01071-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.22.453333","asserted-by":"object"}]},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13073-023-01190-7","URL":"https:\/\/doi.org\/10.1186\/s13073-023-01190-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All rodent experiments were approved by the University of New South Wales Animal Care and Ethics Committee (Project numbers ACEC 11\/82B and 13\/55B).All human research  conformed to the principles of the Helsinki Declaration. Whole genome sequence data for mutation burden comparisons and mutational signature extraction was done on samples as approved by the Cambridge University Hospitals NHS Foundation Trust (16\/NI\/0196). All biological samples were collected with informed consent from Addenbrooke\u2019s Hospital, Cambridge, UK. The human liver samples used for ChIP and quantitative PCR were from human livers which had been rejected for transplantation acquired through the King\u2019s College Hospital, London. The ethics approval for hepatocyte biology research came from the King\u2019s Healthcare NHS Trust (LREC protocol 1998\u20130249) which covered the use of these samples in the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}